Table 1 Basal clinical characteristics of neoadjuvant patients, n = 12
Characteristic | No. | Percent |
|---|---|---|
Age, years | ||
Mean | 38 | |
Range | 28–56 | |
BRCA1 mutation | ||
Exon 20 c.5266dupC (BIC: 5382insC) | 8 | 66 |
Exon 11 c.4035delA (BIC: 4154delA) | 4 | 34 |
Clinical tumor size | ||
T1 | 5 | 42 |
T2 | 5 | 42 |
T3 | 2 | 17 |
Clinical nodal status | ||
N0 | 6 | 50 |
N1 | 5 | 42 |
N2 | 0 | 0 |
N3 | 1 | 8 |
Estrogen receptor level | ||
Positive | 1 | 8 |
Negative | 10 | 83 |
Missing | 1 | 8 |
Progesterone receptor level | ||
Positive | 1 | 8 |
Negative | 10 | 83 |
Missing | 1 | 8 |
HER2 status | ||
Positive | 1 | 8 |
Negative | 8 | 66 |
Missing | 3 | 25 |
Differentiation | ||
Grade I | 0 | 0 |
Grade II | 4 | 33 |
Grade III | 7 | 58 |
Missing | 1 | 8 |
Histology | ||
Ductal | 10 | 83 |
Medullary | 1 | 8 |
Missing | 1 | 8 |
Chemotherapy | ||
Cisplatin + Doxorubicin | 11 | 92 |
Carboplatin + Docetaxel | 1 | 8 |
Pathological remission | ||
Complete | 10 | 83 |
Partial | 2 | 17 |
Salpingoopherectomy | ||
No | 7 | 58 |
Yes | 5 | 42 |
Postoperative radiation | ||
No | 8 | 66 |
Yes | 4 | 33 |